Confused by conflicting studies about the link between viagra and Alzheimer’s? Two experts explain the disparaties
L’expertise universitaire, l’exigence journalistique
Articles sur Lecanemab
Ensemble des articles
Despite decades of starts and stops, new treatments and key genetic discoveries are giving researchers great hope for slowing or eventually preventing Alzheimer’s disease.
In clinical trials, lecanemab slowed disease progression by 27% and reduced the amount of plaque found in the brains of those with Alzheimer’s disease.
An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
Two new dementia drugs are being hailed as breakthroughs. But what might be an incremental breakthrough for researchers, doesn’t mean a cure for patients.
Lecanemab slows progression of early-stage Alzheimer’s disease in some, new study shows. But the ‘adverse events’ are significant.
Lecanemab, an experimental dementia drug, slowed cognitive decline by 27% in late-stage clinical trials.
Les contributeurs les plus fréquents
-
Associate Professor, Turner Institute for Brain and Mental Health, Monash University
-
Étudiant au doctorat en psychologie, Université du Québec à Montréal (UQAM)
-
Postdoctoral Research Fellow (Neuropsychology), Monash University
-
Director of Research, Associate Professor in Therapeutics, University of Bradford
-
Clinical Professor of Ageing, Queen's University Belfast
-
Associate Professor in Dementia Neurology, University of Bristol
-
Professor of Neurology, University of Miami
-
Professeur, Université Laval
-
Post Doctoral Research Assistant, University of Bradford
-
Professor of Neurology and Neuroscience, University of Florida
-
Professor in Clinical Pharmacy, Aston University
-
Senior lecturer in Pharmacoepidemiology, Aston University
